David Piontkowsky

Statistics

Publications

Citations

523

H-Index

Active since

2002

Affiliations

Gilead Sciences (United States)(Current)

Délégation Paris 7

Université Paris Cité

Ospedale Papa Giovanni XXIII

Hospital General Universitario Gregorio Marañón

David Piontkowsky is an author at Gilead Sciences (United States) specializing in antiretroviral therapy, antiviral pharmacotherapy, and antiviral therapy.

Publications per year

2002–2022

Publications

Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial

José Ramón Arribas, Gilles Pialoux, Joseph Gathe et al. · The Lancet Infectious Diseases · 2014 · 116 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial

Anton Pozniak, Martin Markowitz, Anthony Mills et al. · The Lancet Infectious Diseases · 2014 · 99 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial

Giuliano Rizzardini, Jean‐Michel Molina, Federico Pulido et al. · Infectious Diseases and Therapy · 2021 · 50 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen

Rafael Campo, E DeJesus, U. Fritz Bredeek et al. · Clinical Infectious Diseases · 2013 · 49 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial

Giuliano Rizzardini, François Raffi, Federico Pulido et al. · The Lancet HIV · 2019 · 43 citations

Pharmacy, Pharmacokinetics, Pharmacotherapy +16

1–5 of 13